Special Drug Use Result Survey of IMAAVY in patients with generalized myasthenia gravis (limited to patients who do not sufficiently respond to steroids or immunosuppressants other than steroids)

Special Drug Use Result Survey of IMAAVY in patients with generalized myasthenia gravis (limited to patients who do not sufficiently respond to steroids or immunosuppressants other than steroids) - IMA1L

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059519

Enrollment

150

Registered

2025-10-29

Start date

2025-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

generalized myasthenia gravis (limited to patients who do not sufficiently respond to steroids or immunosuppressants other than steroids)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are receiving their first administration of this drug for generalized myasthenia gravis(limited to patients who do not sufficiently respond to steroids or immunosuppressants other than steroids) .

Exclusion criteria

Exclusion criteria: Patients with prior use of IMAAVY

Design outcomes

Primary

Measure	Time frame
1)Occurrence of safety specifications (infections) 2)Relationship between changes in total IgG levels and the occurrence and seriousness of infections 3)Factors that may affect the onset of infection (e.g., onset status by patient background) 4)Incidence of adverse drug reactions	—

Countries

Japan

Contacts

Public ContactAsami Otsuka

Janssen Pharmaceutical K.K. Medical Affairs Delivery Unit

aotsuka@its.jnj.com070-2668-6638

Outcome results